Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2017

Open Access 01-12-2017 | Research article

Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity

Authors: Sedigheh Shams, Maliheh Barazandeh Tehrani, Gabriel Civallero, Koosha Minookherad, Roberto Giugliani, Aria Setoodeh, Mohammad Taghi Haghi Ashtiani

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2017

Login to get access

Abstract

Background

Mucopolysaccharidosis type IVA, also known as Morquio A or MPS IV A, is an autosomal recessive disease caused by the deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). The loss of GALNS activity leads to the impaired breakdown of glycosaminoglycans (GAGs) keratan sulfate and chondroitin-6-sulfate. The accumulation of GAGs results in multiple organ damage. The accurate and early diagnosis of this disorder helps enhance the effectiveness of the treatment. The present study uses a pre-designed protocol for testing GALNS activity in the leukocytes of Iranian patients with MPS IV A and their parents and compares it with healthy controls.

Methods

Patients with MPS IVA previously diagnosed through the measurement of enzyme activity or genetic analysis entered the study. Leukocytes were obtained from the heparinized blood of the participants. The GALNS activity was measured by a fluorometric method using 4-methylumbelliferyl-β-D-galactoside-6-sulfate (4MU-G6S) as the substrate and proper buffer solutions and calibrators.

Results

The GALNS activity (nmol/17 h/mg protein) was reported as 0–7.4 in the MPSIV A patients, as 19.85–93.7 in their parents and as 38.4–164 in the healthy controls. Statistically significant differences were observed between the three groups in terms of enzyme activity. There were no significant differences in enzyme activity by age. The female subjects in both the patient and parents groups showed lower enzyme activity compared to the male subjects.

Conclusion

The fluorometric method was validated for the measurement of GALNS activity in leukocyte samples and identifying Iranian patients with MPS IV A.
Literature
4.
go back to reference Khedhiri S, Chkioua L, Bouzidi H, Dandana A, Ben Turkia H, Miled A, Laradi S. Mucopolysaccharidosis type I and IVA: clinical features and consanguinity in Tunisia. Pathol Biol (Paris). 2009; 57(5):392–397. doi:10.1016/j.patbio.2008.05.005. Khedhiri S, Chkioua L, Bouzidi H, Dandana A, Ben Turkia H, Miled A, Laradi S. Mucopolysaccharidosis type I and IVA: clinical features and consanguinity in Tunisia. Pathol Biol (Paris). 2009; 57(5):392–397. doi:10.​1016/​j.​patbio.​2008.​05.​005.
8.
go back to reference Berry HK. Screening for mucopolysaccharide disorders with the berry spot test. Clin Biochem. 1987;20(5):365–71.CrossRefPubMed Berry HK. Screening for mucopolysaccharide disorders with the berry spot test. Clin Biochem. 1987;20(5):365–71.CrossRefPubMed
9.
go back to reference Whitley CB, Ridnour MD, Draper KA, Dutton CM, NeglIa JP. Diagnostic test for Mucopolysaccharidosis.I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem. 1989;35(3):374–9.PubMed Whitley CB, Ridnour MD, Draper KA, Dutton CM, NeglIa JP. Diagnostic test for Mucopolysaccharidosis.I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem. 1989;35(3):374–9.PubMed
10.
go back to reference Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clinica chimica acta; international journal of clinical chemistry. 2004;345(1–2):135–40.CrossRefPubMed Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clinica chimica acta; international journal of clinical chemistry. 2004;345(1–2):135–40.CrossRefPubMed
11.
go back to reference Zaia J. Pinciples of mass spectrometry of glycosaminoglycans. Journal of Biomacromolecular Mass Spectrometry. 2005;1(1):3–36. Zaia J. Pinciples of mass spectrometry of glycosaminoglycans. Journal of Biomacromolecular Mass Spectrometry. 2005;1(1):3–36.
12.
go back to reference Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2014;2(9):135. doi:10.1186/s13023-014-0135-3.CrossRef Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2014;2(9):135. doi:10.​1186/​s13023-014-0135-3.CrossRef
13.
go back to reference Tomatsu S, Shimada T, Mason RW, Kelly J, LaMarr WA, Yasuda E, et al. Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech 2014, S2 doi:10.4172/2155-9872.S2-006 Tomatsu S, Shimada T, Mason RW, Kelly J, LaMarr WA, Yasuda E, et al. Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech 2014, S2 doi:10.​4172/​2155-9872.​S2-006
15.
go back to reference Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, et al. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clin Ther. 2015; 37(5):1012–1021.e6. doi:10.1016/j.clinthera.2014.11.005. Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, et al. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clin Ther. 2015; 37(5):1012–1021.e6. doi:10.​1016/​j.​clinthera.​2014.​11.​005.
16.
go back to reference Burton BK, Berger KI, Lewis GD, Tarnopolsky M5, Treadwell M6, Mitchell JJ, et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio A syndrome: A randomized, double-blind, pilot study. Am J Med Genet A. 2015;167A(10):2272-81. doi:10.1002/ajmg.a.37172. Burton BK, Berger KI, Lewis GD, Tarnopolsky M5, Treadwell M6, Mitchell JJ, et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio A syndrome: A randomized, double-blind, pilot study. Am J Med Genet A. 2015;167A(10):2272-81. doi:10.​1002/​ajmg.​a.​37172.
17.
go back to reference Van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Poorthuis BJHM, Van Pelt J, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type a (MPS IVA). Cilinica Chimica Acta. 1990;187:131–40.CrossRef Van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Poorthuis BJHM, Van Pelt J, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type a (MPS IVA). Cilinica Chimica Acta. 1990;187:131–40.CrossRef
18.
go back to reference Skoog WA, Beck WS. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood. 1956;11:436–54.PubMed Skoog WA, Beck WS. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood. 1956;11:436–54.PubMed
19.
go back to reference Camelier MV, Burin MG, De Mari J, Vieira TA, Marasca G, Giugliani R. Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clin Chim Acta. 2011; 18; 412(19–20):1805–1808. doi:10.1016/j.cca.2011.06.001. Camelier MV, Burin MG, De Mari J, Vieira TA, Marasca G, Giugliani R. Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clin Chim Acta. 2011; 18; 412(19–20):1805–1808. doi:10.​1016/​j.​cca.​2011.​06.​001.
20.
go back to reference Olarte-Avellaneda S, Rodrıguez-Lopez A, Almeciga-Diaz CJ, Barrera LA. Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype–phenotype correlation for Morquio A. Mol Biol Rep. 2014;41:7073–88. doi:10.1007/s11033-014-3383-3.CrossRefPubMed Olarte-Avellaneda S, Rodrıguez-Lopez A, Almeciga-Diaz CJ, Barrera LA. Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype–phenotype correlation for Morquio A. Mol Biol Rep. 2014;41:7073–88. doi:10.​1007/​s11033-014-3383-3.CrossRefPubMed
21.
go back to reference Ullal AJ, Millington DS, Bali DS. Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots. Molecular Genetics and Metabolism Reports 1. 2014; 461–464. doi:10.1016/j.ymgmr.2014.10.004. Ullal AJ, Millington DS, Bali DS. Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots. Molecular Genetics and Metabolism Reports 1. 2014; 461–464. doi:10.​1016/​j.​ymgmr.​2014.​10.​004.
Metadata
Title
Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity
Authors
Sedigheh Shams
Maliheh Barazandeh Tehrani
Gabriel Civallero
Koosha Minookherad
Roberto Giugliani
Aria Setoodeh
Mohammad Taghi Haghi Ashtiani
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2017
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-017-0319-1

Other articles of this Issue 1/2017

Journal of Diabetes & Metabolic Disorders 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine